AI
Wednesday, June 15, 2016 8:29:26 AM
Lisa Stepp (PhD, Sen.Dir/MedicalAffairs) speaking 9-15-16 at Medical-Affairs-Forum
Sept14-16 2016: “EXL's 11th Medical Affairs Executive Forum”, SanDiego
http://exlevents.com/medical-affairs-executive-forum-west
“The role of medical affairs teams in the life science industry has seen an expansion of functionality & responsibility, especially with easier access to information through digital platforms. A primary focus for medical affairs leadership is to ensure the compliant separation of clinical & commercial teams, particularly regarding their access to therapeutic area experts. Communication channel mgt. will serve as one of the driving themes for the Medical Affairs Strategic Summit (MASS) West 2016...”
9-15-16 11:15–12pm: “The Effects of Company Size on the Establishment of an Advisory Board Benchmark” - Lisa Stepp, PhD, Sen.Dir./Medical Affairs, Peregrine Pharmaceuticals
- - - -
Lisa Stepp (PhD/MBA) joined Peregrine 3-2015 as “Sr. Dir./Medical Affairs” - formerly with Gilead, Allos, Genentech, and Wyeth.
https://www.linkedin.com/in/lisa-stepp-phd-mba-345942a
= = = = = = = = = = = = = =
2-2016: Rutgers' Dr. Raymond Birge's relationship with Peregrine & UTSW's Dr. Rolf Brekken and his 2-26-16 article, “Phosphatidylserine is a Global Immunosuppressive Signal in Efferocytosis, Infectious Disease, and Cancer” http://tinyurl.com/z5d9qt9
11-9-15 SITC'15: New Bavi+Checkpoint Inhibitors preclin. data (UTSW/DUKE's Herbert K. Lyerly) http://tinyurl.com/pbof95w
...Also, collab. with Dr. Bernard Fox (Immunotherapist/Earle A. Chiles Res.Inst.) on new Immuno-Profiling Clinical Test (Opal 6-plex quantitative IF Assay), PPHM roundtable with Raymond Birge (Rutgers), Douglas Graham (Emory), Dmitry Gabrilovich (Wistar), Rolf Brekken (UTSW), Maria Karasarides (AstraZeneca) - ”Combining Bavi w/anti-PD-1 significantly enhanced O/S… significant incr. CD45+, CD8+ and CD3+ T-cells… led a prolonged anti-tumor immune response which protected the animals against a re-challenge w/same tumor.”
5-31-15: ASCO’15 Roundtable (webcast), “Raising the Immuno-Oncology Bar” - 7 panel members, incl. 3 Mem. Sloan Kettering researchers http://tinyurl.com/qxu4w2x
BAVI MOA 3-25-14: Dr. Rolf Brekken’s 40min talk at NYAS Lung Cancer Symposium http://tinyurl.com/lq9stnk (45 Slides)
. . .Dr.Brekken’s talk: “Antibody-mediated Inhibition of PS - A Novel Strategy for Immune Checkpoint Blockade” (the 5 speakers: Jessica Donington, Roy Herbst, Balazs Halmos, Suresh Ramalingam, Rolf Brekken)
12-10-13: With recent scientific insights highlighting bavi’s immunostimulatory moa, these additions to PPHM’s SAB: Dimitry Gabrilovich, Scott Antonia, David Carbone**, Hakan Mellstedt http://tinyurl.com/mw776mk
......**A/o 9-2015, Dr. David Carbone (PPHM SAB/KOL) is President of IASLC https://www.iaslc.org/about-us/board
http://www.peregrineinc.com/about-us/medical-and-scientific-advisors.html
Sept14-16 2016: “EXL's 11th Medical Affairs Executive Forum”, SanDiego
http://exlevents.com/medical-affairs-executive-forum-west
“The role of medical affairs teams in the life science industry has seen an expansion of functionality & responsibility, especially with easier access to information through digital platforms. A primary focus for medical affairs leadership is to ensure the compliant separation of clinical & commercial teams, particularly regarding their access to therapeutic area experts. Communication channel mgt. will serve as one of the driving themes for the Medical Affairs Strategic Summit (MASS) West 2016...”
9-15-16 11:15–12pm: “The Effects of Company Size on the Establishment of an Advisory Board Benchmark” - Lisa Stepp, PhD, Sen.Dir./Medical Affairs, Peregrine Pharmaceuticals
- - - -
Lisa Stepp (PhD/MBA) joined Peregrine 3-2015 as “Sr. Dir./Medical Affairs” - formerly with Gilead, Allos, Genentech, and Wyeth.
https://www.linkedin.com/in/lisa-stepp-phd-mba-345942a
= = = = = = = = = = = = = =
2-2016: Rutgers' Dr. Raymond Birge's relationship with Peregrine & UTSW's Dr. Rolf Brekken and his 2-26-16 article, “Phosphatidylserine is a Global Immunosuppressive Signal in Efferocytosis, Infectious Disease, and Cancer” http://tinyurl.com/z5d9qt9
11-9-15 SITC'15: New Bavi+Checkpoint Inhibitors preclin. data (UTSW/DUKE's Herbert K. Lyerly) http://tinyurl.com/pbof95w
...Also, collab. with Dr. Bernard Fox (Immunotherapist/Earle A. Chiles Res.Inst.) on new Immuno-Profiling Clinical Test (Opal 6-plex quantitative IF Assay), PPHM roundtable with Raymond Birge (Rutgers), Douglas Graham (Emory), Dmitry Gabrilovich (Wistar), Rolf Brekken (UTSW), Maria Karasarides (AstraZeneca) - ”Combining Bavi w/anti-PD-1 significantly enhanced O/S… significant incr. CD45+, CD8+ and CD3+ T-cells… led a prolonged anti-tumor immune response which protected the animals against a re-challenge w/same tumor.”
5-31-15: ASCO’15 Roundtable (webcast), “Raising the Immuno-Oncology Bar” - 7 panel members, incl. 3 Mem. Sloan Kettering researchers http://tinyurl.com/qxu4w2x
BAVI MOA 3-25-14: Dr. Rolf Brekken’s 40min talk at NYAS Lung Cancer Symposium http://tinyurl.com/lq9stnk (45 Slides)
. . .Dr.Brekken’s talk: “Antibody-mediated Inhibition of PS - A Novel Strategy for Immune Checkpoint Blockade” (the 5 speakers: Jessica Donington, Roy Herbst, Balazs Halmos, Suresh Ramalingam, Rolf Brekken)
12-10-13: With recent scientific insights highlighting bavi’s immunostimulatory moa, these additions to PPHM’s SAB: Dimitry Gabrilovich, Scott Antonia, David Carbone**, Hakan Mellstedt http://tinyurl.com/mw776mk
......**A/o 9-2015, Dr. David Carbone (PPHM SAB/KOL) is President of IASLC https://www.iaslc.org/about-us/board
http://www.peregrineinc.com/about-us/medical-and-scientific-advisors.html
